We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

47 hedge funds and large institutions have $113M invested in Inhibikase Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

533% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 3

300% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 3

52% more funds holding

Funds holding: 31 → 47 (+16)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5.3% less ownership

Funds ownership: 74.53% → 69.23% (-5.3%)

31% less capital invested

Capital invested by funds: $163M → $113M (-$50M)

Holders
47
Holders Change
+16
Holders Change %
+51.61%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
12
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.94M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.27M
3
Marshall Wace
Marshall Wace
United Kingdom
+$390K
4
Goldman Sachs
Goldman Sachs
New York
+$307K
5
Jane Street
Jane Street
New York
+$292K

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$1.46M
2
SCM
Stonepine Capital Management
Oregon
-$546K
3
Citigroup
Citigroup
New York
-$129K
4
AGM
Alpine Global Management
New York
-$96.5K
5
Squarepoint
Squarepoint
New York
-$92.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$98.6K +$102K +40,517 +899%
State Street
27
State Street
Massachusetts
$91.7K – – –
Qube Research & Technologies (QRT)
28
Qube Research & Technologies (QRT)
United Kingdom
$78K +$89.5K +35,625 New
ECM
29
ExodusPoint Capital Management
New York
$71K +$81.7K +32,538 New
LP
30
LMR Partners
United Kingdom
$68.1K +$78.1K +31,092 New
DC
31
Diametric Capital
Massachusetts
$62.1K +$71.3K +28,366 New
YIH
32
Y-Intercept (HK)
Hong Kong
$58.6K +$67.3K +26,775 New
Citigroup
33
Citigroup
New York
$56.4K -$129K -51,335 -67%
Morgan Stanley
34
Morgan Stanley
New York
$47.4K +$36K +14,350 +197%
SSA
35
Schonfeld Strategic Advisors
New York
$37K +$42.4K +16,876 New
CC
36
Caxton Corporation
New Jersey
$35.9K – – –
PAS
37
Point72 Asia (Singapore)
Singapore
$32.8K +$37.6K +14,976 New
JFG
38
Jefferies Financial Group
New York
$32.4K – – –
CFM
39
Catalyst Funds Management
Australia
$30K +$34.4K +13,712 New
Stifel Financial
40
Stifel Financial
Missouri
$28.8K – – –
QC
41
Quantessence Capital
New York
$28.5K +$32.7K +13,005 New
PCM
42
Prelude Capital Management
New York
$24.3K +$27.9K +11,098 New
Capstone Investment Advisors
43
Capstone Investment Advisors
New York
$24.2K +$27.8K +11,067 New
BHCM
44
Brevan Howard Capital Management
Jersey
$22.7K +$26.1K +10,384 New
CSS
45
Cubist Systematic Strategies
Connecticut
$19.8K +$22.7K +9,043 New
PD
46
Point72 (DIFC)
United Arab Emirates
$4.34K +$4.97K +1,980 New
Wells Fargo
47
Wells Fargo
California
$366 – – –
AGM
48
Alpine Global Management
New York
– -$96.5K -29,684 Closed
Squarepoint
49
Squarepoint
New York
– -$92.3K -28,411 Closed
SAM
50
Synergy Asset Management
Washington
– -$65 -50 Closed
1
2

IKT Hedge Fund Activity: Q1 2025 in Review

47 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2025, worth a combined $113M — down 31% from $163M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new IKT positions and 3 closed out — a net gain of 16 holders — while 12 added to existing stakes and 3 trimmed.

The largest buyer was Millennium Management, adding an estimated $1.94M. The largest seller was Commodore Capital, cutting an estimated $1.46M.

  • 47 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2025, up from 31 in Q4 2024.
  • Funds reported $113M of Inhibikase Therapeutics stock for Q1 2025, down 31% quarter-over-quarter.
  • 19 funds opened new Inhibikase Therapeutics positions in Q1 2025 and 3 closed out, a net change of +16 holders.
  • The largest Inhibikase Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $1.94M added.
  • The largest Inhibikase Therapeutics seller in Q1 2025 was Commodore Capital, an estimated $1.46M sold.

Based on aggregated 13F filings for Q1 2025.